目的探討孟魯司特聯(lián)合沙丁胺醇氣霧劑治療咳嗽變異性哮喘的療效及對炎癥因子的影響。方法選取2015年1月-2016年1月渭南市婦幼保健院兒科收治的咳嗽變異性哮喘患者120例,隨機平均分配為觀察組和對照組,對照組僅給予沙丁胺醇氣霧劑治療,觀察組給予孟魯司特聯(lián)合沙丁胺醇氣霧劑治療。比較兩組患者的臨床療效、患者肺功能恢復情況以及血清中炎癥因子變化情況。結(jié)果治療2個月后,對照組和觀察組的有效率分別為73.3%和96.7%,觀察組的有效率明顯高于對照組,兩組比較差異顯著（P<0.05）。治療前,兩組患者FEV1、FEV1/FVC等肺功能相關(guān)的指標無統(tǒng)計學差異。治療后,兩組患者FEV1、FEV1/FVC均顯著升高,與治療前比較差異顯著（P<0.05）；且觀察組明顯高于對照組,兩組比較差異顯著（P<0.05）。治療前,兩組患者血清IL-6、TNF-α水平無顯著差異；治療后,兩組患者IL-6、TNF-α水平均顯著降低,與治療前比較差異顯著（P<0.05）；且觀察組患者治療血清IL-6、TNF-α水平顯著低于對照組（P<0.05）。結(jié)論采用孟魯司特聯(lián)合沙丁胺醇氣霧劑治療咳嗽變異性哮喘安全有效,可顯著改善患者肺功能并降低炎癥因子水平。

Objective To investigate the effect and influence on inflammatory factors of salbutamol aerosol combined with montelukast in treatment of cough variant asthma. Methods From Jan 2015 to Jan 2016, 120 cases of cough variant asthma in our hospital were selected as the subjects. They were randomly and equally divided into 2 groups:control group (n=60) were treated with salbutamol aerosol, and observation group were treated with salbutamol aerosol and montelukast. The clinical effects, the pulmonary function and the serum inflammatory factors were compared between the two groups. Results After 2 months of treatment, the effective rate of the control group and the observation group were 73.3% and 96.7% respectively, there was statistical differences between two groups (P < 0.05). The FEV1 and FEV1/FVC of both groups showed remarkable increase. The FEV1, FEV1/FVC of observation group were (2.21 ±0.17) L、(66.10 ±4.46)%, and the FEV1, FEV1/FVC of control group (1.82 ±0.11) L、 (52.48 ±3.34)%. The difference between two groups was statistically significant (P < 0.05). The IL-6 and TNF-α of both groups showed remarkable decrease. IL-6 and TNF-α in observation group were significantly lower than those of control group (14.58 ±2.90 vs. 20.87 ±3.26, P < 0.05; 0.59 ±0.12 vs. 0.97 ±0.15, P < 0.05). Conclusion The use of montelukast combined with salbutamol aerosol in the treatment of cough variant asthma was safe and effective, and could significantly improve pulmonary function and reduce inflammatory factor.